Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following the company’s decision to trim its 2025 financial outlook.

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its full-year sales and profit outlook for the second time this year. The announcement,

Novo Nordisk’s plummet is a warning for backers who’ve crowded into a relatively small group of very large stocks.

First, a drug like Ozempic mimics the natural GLP-1 hormone in your gut, which slows down digestion in the stomach and gastrointestinal tract. Those who take it feel fuller earlier and longer, and it’s easier for them to eat less. The better regulation of blood sugar also prevents massive swings in glucose, which can induce hunger.

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare eye condition known

While Ozempic is effective at treating type 2 diabetes and supporting weight loss, it can also come with side effects. Fatigue is one that some people notice, so if you’ve been feeling tired or run down after starting Ozempic,

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave patients with loose,

On Tuesday, Novo took an axe to its financial outlook in a surprise corporate update call where it replaced its CEO with an insider who seeks to tame worries about the company's declining market share in the diabetes and obesity marketplace.

Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type 2 diabetes. But as their popularity grows, so do questions about possible mental health side effects,